| scholarly article | Q13442814 |
| P2093 | author name string | Thompson V | |
| Sandy JD | |||
| Gamett D | |||
| Verscharen C | |||
| P2860 | cites work | The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain | Q24293718 |
| Fluorometric assay of DNA in cartilage explants using Hoechst 33258. | Q35124134 | ||
| Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance | Q41179543 | ||
| Cell-mediated catabolism of aggrecan. Evidence that cleavage at the "aggrecanase" site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain | Q41370351 | ||
| Inhibition of glycosylphosphatidylinositol anchor formation by mannosamine | Q41598536 | ||
| Chemical decomposition of glutamine in cell culture media: effect of media type, pH, and serum concentration | Q41743417 | ||
| Mechanism of catabolism of aggrecan by articular cartilage | Q41850195 | ||
| Intermediary metabolism in the Swarm rat chondrosarcoma chondrocyte | Q42014806 | ||
| Suppression of human natural killer cell activity by amino sugars | Q42198557 | ||
| A cartilage explant system for studies on aggrecan structure, biosynthesis and catabolism in discrete zones of the mammalian growth plate | Q42511858 | ||
| Transforming growth factor beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures | Q42513738 | ||
| N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage | Q42682254 | ||
| Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants | Q43783103 | ||
| Inhibitory effect of D-glucosamine on glycolysis in bovine retina | Q44824518 | ||
| Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. | Q49111631 | ||
| Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. | Q50538904 | ||
| Broad specificity hexose transport system with differential mobility of loaded and empty carrier, but directional symmetry, is common property of mammalian cell lines. | Q52739554 | ||
| The recovery of articular cartilage in explant culture from interleukin-1α: Effects on proteoglycan synthesis and degradation | Q60454903 | ||
| Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage | Q67728172 | ||
| Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium | Q68149442 | ||
| Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain | Q70146875 | ||
| Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage | Q70713946 | ||
| Pathways of aggrecan processing in joint tissues. Implications for disease mechanism and monitoring | Q70879867 | ||
| IL-1 beta, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: relevance to peritonitis in CAPD | Q71717750 | ||
| Fibronectin fragment mediated cartilage chondrolysis. I. Suppression by anti-oxidants | Q71847802 | ||
| The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis | Q72547392 | ||
| Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation | Q72633063 | ||
| Relationship between cellular ATP content and cellular functions of primary cultured rat hepatocytes in hypoxia | Q73322352 | ||
| Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors | Q73606695 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tretinoin | Q29417 |
| interleukins | Q194908 | ||
| glucosamine | Q32907954 | ||
| P304 | page(s) | 59-66 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine | |
| P478 | volume | 335 ( Pt 1) |
| Q33678954 | 10mM glucosamine prevents activation of proADAMTS5 (aggrecanase-2) in transfected cells by interference with post-translational modification of furin |
| Q34606492 | ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. |
| Q28203390 | ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors |
| Q41810073 | ADAMTS4 (aggrecanase-1) cleaves human brain versican V2 at Glu405-Gln406 to generate glial hyaluronate binding protein |
| Q34109859 | Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation |
| Q44025451 | Age-related changes in the composition and mechanical properties of human nasal cartilage |
| Q34034399 | Aging and the etiopathogenesis and treatment of osteoarthritis |
| Q37408063 | Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage |
| Q43000076 | Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing i |
| Q35666160 | Biological basis for the benefit of nutraceutical supplementation in arthritis |
| Q37020871 | Characterization of proteoglycan production and processing by chondrocytes and BMSCs in tissue engineered constructs |
| Q35196931 | Chondroprotective agents: glucosamine and chondroitin |
| Q36309644 | Chondroprotective drugs in degenerative joint diseases |
| Q33632751 | Comparison of glucose derivatives effects on cartilage degradation |
| Q24630640 | Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties |
| Q54418168 | Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. |
| Q43076770 | Dietary glucosamine under question |
| Q37199641 | Drug insight: aggrecanases as therapeutic targets for osteoarthritis. |
| Q41636872 | Effect of Glucosamine Sulfate on Osteoarthritis in the Cruciate-Deficient Canine Model of Osteoarthritis |
| Q44159772 | Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits |
| Q34556616 | Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis |
| Q35147261 | Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids |
| Q46801560 | Effects of hexosamines and omega-3/omega-6 fatty acids on pH regulation by interleukin 1-treated isolated bovine articular chondrocytes |
| Q44525457 | Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage |
| Q34109134 | Evidence of nutriceutical effectiveness in the treatment of osteoarthritis |
| Q42995635 | Evidence that the inhibition of cartilage proteoglycan breakdown by mannosamine is not mediated via inhibition of glycosylphosphatidylinositol anchor formation |
| Q35630056 | Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta |
| Q32081150 | Expression and activity of ADAMTS-5 in synovium |
| Q24792782 | Fc gamma R expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA) |
| Q57957374 | Five percent oxygen tension is not beneficial for neocartilage formation in scaffold-free cell cultures |
| Q44443585 | Functional characterisation of glucose transport in bovine articular chondrocytes |
| Q38362244 | Glucosamine Hydrochloride but Not Chondroitin Sulfate Prevents Cartilage Degradation and Inflammation Induced by Interleukin-1α in Bovine Cartilage Explants |
| Q40070187 | Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. |
| Q24805719 | Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report |
| Q41176136 | Glucosamine exposure reduces proteoglycan synthesis in primary human endothelial cells in vitro |
| Q33368886 | Glucosamine increases hyaluronic acid production in human osteoarthritic synovium explants |
| Q44394411 | Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes |
| Q22000860 | Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation |
| Q34534426 | Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes |
| Q46013166 | Glucosamine sulphate does not increase extracellular matrix production at low oxygen tension. |
| Q36901726 | Glucosamine supplementation demonstrates a negative effect on intervertebral disc matrix in an animal model of disc degeneration |
| Q74096691 | Intact aggrecan and fragments generated by both aggrecanse and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury |
| Q32067938 | Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes |
| Q50280462 | Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage. |
| Q21195259 | Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? |
| Q32050561 | Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial |
| Q35636751 | Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness |
| Q36209436 | Nutraceutical therapies for degenerative joint diseases: a critical review. |
| Q34636799 | Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities |
| Q34515154 | Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants |
| Q47151673 | Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of normal joint cartilage pursuant to Article 13(5) of Regulation (EC) No 1924/2006 |
| Q35652515 | Structure-modifying agents for osteoarthritis: an update |
| Q34383021 | Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses |
| Q42997615 | The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1. |
| Q37825835 | The role of ADAMTSs in arthritis |
| Q45127723 | The use of glucosamine therapy in osteoarthritis |
| Q35624596 | The use of glucosamine therapy in osteoarthritis |
| Q28207975 | Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4 |
Search more.